---
title: Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory
  Large B-cell Lymphoma
date: '2024-08-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39187161/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240828181953&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS: Based on these findings, prophylactic tocilizumab is not
  recommended to prevent CAR T-cell-related adverse events, and beneficial effects
  of prophylactic levetiracetam remain uncertain in patients with R/R ...'
disable_comments: true
---
CONCLUSIONS: Based on these findings, prophylactic tocilizumab is not recommended to prevent CAR T-cell-related adverse events, and beneficial effects of prophylactic levetiracetam remain uncertain in patients with R/R ...